Capital Group U.S. Multi-Sector Income ETF (CGMS)
- Previous Close
27.94 - Open
27.91 - Bid 27.91 x 2200
- Ask 27.92 x 1000
- Day's Range
27.90 - 27.94 - 52 Week Range
25.00 - 28.00 - Volume
148,970 - Avg. Volume
498,798 - Net Assets 1.21B
- NAV 27.90
- PE Ratio (TTM) --
- Yield 5.94%
- YTD Daily Total Return 7.65%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.39%
The fund normally invests at least 80% of its assets in the securities of issuers domiciled within the United States. The fund invests primarily in bonds and other debt instruments, which may be represented by derivatives. In seeking to achieve a high level of current income, the fund invests in a broad range of debt securities across the credit spectrum. The fund may invest in debt securities of any maturity or duration. The fund is non-diversified.
Capital Group
Fund Family
Multisector Bond
Fund Category
1.21B
Net Assets
2022-10-25
Inception Date
Performance Overview: CGMS
View MoreTrailing returns as of 9/20/2024. Category is Multisector Bond.
People Also Watch
Holdings: CGMS
View MoreSector Weightings
Related ETF News
View MoreResearch Reports: CGMS
View MoreRaising target price to $61.00
EDWARDS LIFESCIENCES CORP has an Investment Rating of SELL; a target price of $61.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about BB?
BLACKBERRY LTD has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetJohnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetNew products and M&A drive 2024 growth
Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
RatingPrice Target